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a  b  s  t  r  a  c  t
The  compatibility  of  fasted  state  simulated  intestinal  ﬂuid  (FaSSIF)  in  drug  permeation  studies  employing
the phospholipid  vesicle-based  permeation  assay  (PVPA)  model  was conﬁrmed  by a set  of  differ-
ent  integrity  indicators.  Neither  calcein  permeability  nor  electrical  resistance  were  found  signiﬁcantly
changed  indicating  unaffected  barrier  tightness.  Furthermore,  the  release  of phospholipid  from  the  bar-
riers in  contact  with  FaSSIF  was  negligible,  although  sodium  taurocholate  disappeared  from  the  donor
– possibly  due  to  transfer  into  the  barrier.  Visual  examination  of the  barrier  structure  by confocal  laser
scanning  microscopy  (CLSM)  revealed  no changes.  The  model  drugs,  cimetidine,  nadolol,  ketoprofen  and
griseofulvin  showed  either  slightly  enhanced  or  unchanged  permeability  values  in  the  presence  of FaS-
SIF. This  may  be  attributed  to micellar  encapsulation  and/or  slight  changes  in  barrier  characteristics.
Particularly  for  poorly  soluble  drugs,  FaSSIF  appeared  favourable  in  terms  of  markedly  improved  recov-
ery.  Moreover,  utilisation  of  BSA  in  the  receiver  compartment  seems  to augment  this  beneﬁcial  effect
on  recovery  rate.  It is likely  that  this  experimental  set-up  affords  better  sink  conditions  in  the  receiver
phase,  which  results  in higher  ﬂuxes.  Overall,  a  combination  of  FaSSIF  in the  donor  phase  and  BSA in  the
receiver  phase  facilitates  improved  experimental  output.
© 2011 Elsevier B.V. All rights reserved.
1. Introduction
Prediction of the absorptive properties of new drug entities
has in recent years become a key component in the industrial
drug development process. Modern drug discovery strategies pro-
vide a steadily increasing number of potential drug candidates
boosting the development of high through-put screening tools for
oral bioavailability prediction. Among these, non-cellular models
based upon artiﬁcial membranes are especially valuable due to
their good reproducibility and comparably low cost (e.g., PAMPA,
PVPA) (Flaten et al., 2006b; Kansy et al., 1998). The phospholipid
vesicle-based permeation assay (PVPA) developed for the screen-
ing of passive permeability, consists of a tight barrier of liposomes
on a ﬁlter support, packed by use of centrifugation (Flaten et al.,
2006a,b). It generates permeability data which correlate well with
the fraction absorbed in humans following oral administration
(Flaten et al., 2006a).  More recently, it has been demonstrated to
be compatible with a variety of co-solvents and surfactants, as well
as at a broad range of pH values (Flaten et al., 2007, 2008).
∗ Corresponding author at. Tel.: +45 65502525; fax: +45 65508780.
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At the same time, the occurrence of increasingly lipophilic and
less water soluble drugs requested the development of alternative
dissolution media. Various additives have been suggested as they
facilitate the wetting of solids and the solubilisation of lipophilic
drugs into micelles (Kimura et al., 1972; Kleberg et al., 2010b; Lehto
et al., 2011; Persson et al., 2005; Schwebel et al., 2011). A general
expectation is that such media mimic  the in vivo dissolution process
more closely than simple buffers. Among the simulated intestinal
ﬂuids (Galia et al., 1998; Kleberg et al., 2010a,b), the most widely
used is the fasted state simulated intestinal ﬂuid (FaSSIF) developed
by Dressman and co-workers (Galia et al., 1998). Encompassing
both bile salt and lipid components, and buffered to a pH of between
6.5 and 6.8, it closely resembles intestinal ﬂuid in its fasted state.
While originally applied as dissolution medium to simulate the
in vivo dissolution behaviour of compounds, it has more recently
been employed as transport medium in permeability investiga-
tions. Indeed, cumulative evidence indicates good applicability of
FaSSIF with the Caco-2 model (Fossati et al., 2008; Ingels et al.,
2002, 2004; Patel et al., 2006). Initial work by Ingels et al. (2002)
illustrated that incubation of Caco-2 monolayers with FaSSIF did
not adversely affect cell viability or barrier integrity. However, the
inﬂuence of FaSSIF on drug permeability is controversial and widely
discussed. Ingels et al. (2004) described that FaSSIF appeared to
0378-5173/$ – see front matter ©  2011 Elsevier B.V. All rights reserved.
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facilitate solubilisation and concomitantly improved ﬂux of poorly
water soluble drugs in suspension. However, it has been suggested
that FaSSIF may  affect active efﬂux mechanisms (i.e., Pgp). Stud-
ies revealed a Pgp inhibitory effect by sodium taurocholate, a bile
salt component of FaSSIF (Brouwers et al., 2006; Ingels et al., 2002,
2004). On the other hand, more recent work by Fossati et al. (2008)
found permeability to be unchanged or depressed.
In this study we sought to investigate the applicability of FaS-
SIF as a transport medium for use in the PVPA in vitro model.
To our knowledge, this is the ﬁrst study into the effect of FaS-
SIF on an in vitro permeability model in which the underlying
transport mechanisms are exclusively passive. Integrity of the
PVPA barrier in the presence of FaSSIF was evaluated by means
of electrical resistance (ER) and calcein permeability, a hydrophilic
marker. The release of phospholipid from the barriers was exam-
ined, and furthermore the barriers were visualised using confocal
laser-scanning microscopy (CLSM). Notably, the bile salt tauro-
cholate, which is a key component of FaSSIF, is known to interact
with phospholipid bilayers (Nichols, 1986; Schubert et al., 1983).
Indeed, numerous studies have explored this effect and the resul-
tant alterations in structure (Schubert et al., 1986; Schubert and
Schmidt, 1988). Thus, we also assessed potential binding of FaS-
SIF with the barrier’s phospholipid bilayers by measuring the loss
of sodium taurocholate from the donor phase. Collectively, our
results indicate that FaSSIF displays good compatibility with the
PVPA in vitro model. In light of this, we examined both the recov-
ery rate and the permeability of four drug compounds (cimetidine,
ketoprofen, nadolol, and griseofulvin) of varying physicochemical
properties in the presence of FaSSIF. Finally, the effect of bovine
serum albumin (BSA) in the receiver compartment on the recovery
and permeability of the poorly soluble compound griseofulvin was
explored.
2. Materials and methods
2.1. Materials
Egg phosphatidyl choline, Lipoid E-80, was kindly provided by
Lipoid GmbH (Ludwigshafen, Germany). Clear Millicell® cell culture
plates (24 well) and mixed cellulose ester ﬁlters (0.65 m pores)
were purchased from Millipore (Copenhagen, Denmark). Costar
transparent 96-well plates were purchased from Corning (Corn-
ing, NY, USA). FaSSiF was prepared by using SIF© instant powder
(Phares, Muttenz, Switzerland) according to the instructions of the
manufacturer, as well as FaSSIF buffer (FaB) (pH 6.5). The phosphate
buffer (PBS) used in liposome preparation and in the receiver com-
partments in permeation experiments contained KH2PO4 0.60 g,
Na2HPO4 × 12H2O 6.40 g, NaCl 7.42 g (1000 ml)  and was  adjusted
to pH 7.4. Calcein, cimetidine, ketoprofen, nadolol, griseofulvin,
sodium taurocholate, bovine serum albumin (fraction V) (BSA) and
all other chemicals were purchased from Sigma–Aldrich (Copen-
hagen, Denmark).
2.2. Preparation of phospholipid vesicle-based barriers
Phospholipid vesicle-based barriers were prepared as described
previously (Flaten et al., 2006b). In brief, mixed cellulose ester ﬁl-
ters (Millipore) were sealed by heat (150 ◦C, 30 s) on clear Millicell®
plates (Millipore) using a custom-made sealing machine (IBR-
Ingenieurbüro, Waldkirch, Germany). Liposomes were made of
egg phosphatidylcholine Lipoid E-80 by ﬁlm hydration with PBS
and subsequent extrusion through polycarbonate ﬁlters (0.4 and
0.8 m).  The liposomes were spun down successively on the ﬁl-
ter inserts: ﬁrst the smaller liposomes to allow them to enter
the pores of the ﬁlter support and then the larger ones to layer
Table 1
Physico-chemical parameters for the model compounds.
Compound MWa pKa b log Pb Aqueous solubility
Cimetidine 252.34 6.80 0.40 5.00c
Nadolol 309.40 9.39 0.71 8.33c
Ketoprofen 254.28 4.60 3.12 0.051c
Griseofulvin 352.77 – 2.18 0.030d
a Molecular weight in g/mol.
b From Hansch et al. (1990).
c From Thomas et al. (2008) in mg/ml  (unbuffered).
d From Mithani et al. (1996) in mg/ml.
on top. The inserts were frozen at −80 ◦C and thawed at 65 ◦C
resulting in fusion of the liposomes so that tight barriers were
obtained.
2.3. Preparation of sample solutions
All drug solutions were prepared in FaB and FaSSIF and were
adjusted to pH 6.5. The griseofulvin solution was  prepared by dilu-
tion of a DMSO stock solution with FaB or FaSSIF, where DMSO did
not exceed 0.5%. The concentration of the hydrophilic marker cal-
cein was 10 mM,  while the concentrations of the model drugs used
were 4.6 mM (ketoprofen), 8 mM (nadolol), 8 mM (cimetidine) and
0.1 mM (griseofulvin). The calcein concentration of 10 mM  is appro-
priate to provide reliable permeability data (Flaten et al., 2008). The
concentrations of the model drugs were chosen to be well below
the saturation limits (at pH 6.5) and at the same time to yield reli-
ably detectable receiver concentrations during permeation studies.
For additional information regarding the model drugs, an overview
of their physicochemical properties is provided in Table 1.
2.4. Confocal laser-scanning microscopy (CLSM)
The liposome barriers were prepared as described above, with
the exception that 0.2 mol% of the egg phospholipid was displaced
by the ﬂuorophore LissamineTM rhodamine B 1,2-dihexadecanoyl-
sn-glycero-3-phosphoethanolamine (Rh-DHPE) (Kirjavainen et al.,
1996). The incubations were performed as described above. Using
a scalpel, the barriers and ﬁlters were gently removed from the
inserts and placed on a microscope slide. The ﬂuorophores were
stabilised by the addition of Vectashield mounting media (Vector
Laboratories, Peterborough, United Kingdom) and the barrier was
covered with a cover slip. The sample was examined under a con-
focal laser-scanning microscope (CLSM; Zeiss LSM 510, Göttingen,
Germany). Rh-DHPE was  excited by use of a laser with a wavelength
of 543 nm.
2.5. Phospholipid release assay
Phospholipids B – enzymatic colorimetric method was  pur-
chased from MTI  Diagnostics (Idstein, Germany). The assay was
performed using a modiﬁed setup that enables utilisation of 96-
well plates (Grohganz et al., 2003). Brieﬂy, the colouring reagent
solution was prepared by adding 20 mL  of buffer solution (contain-
ing 5 mM Tris buffer, 0.34 mM calcium chloride, and 20 mM phenol)
to the dry colouring reagent (phospholipase D 0.44 U/ml, choline
oxidase 2 U/ml, peroxidase 5.3 U/ml, 4-aminophen 0.74 mM).  Fol-
lowing 4 h incubation of the phospholipid vesicle-based barriers
(donor phase) with FaB, FaSSIF, and Triton X-100 0.5% solution (pos-
itive control), samples were taken and diluted with Triton X-100
solution so that a ﬁnal concentration of 1% was achieved. Then,
50 l of each sample was  transferred into individual wells of a
96-well plate to which 250 L of colouring reagent was  added.
Standards were prepared by dissolving E-80 in PBS containing 1%
Triton X-100. The 96-well plates were warmed to 37 ◦C and initially
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shaken for 5 min. A blank consisting of FaSSIF alone was  also used
and subsequently subtracted from the absorbance values acquired
for the FaSSIF samples. After 45 min  incubation and completion
of the reaction, quantiﬁcation was performed by measuring the
absorbance at  = 492 nm.  All samples were prepared and measured
in triplicate.
2.6. Loss of sodium taurocholate
In order to assess any potential interaction of sodium tauro-
cholate in the FaSSIF with the phospholipid vesicle-based barriers,
the loss of sodium taurocholate in the donor phase was mea-
sured while the barriers were incubated with FaSSIF. In addition,
a blank consisting of FaSSIF alone on a ﬁlter was carried out in
a similar manner to that of the barrier samples. Samples from
the donor phase were taken at different time points (1–4 h) and
analysed by HPLC. The loss of sodium taurocholate in % (Loss TC)
was then calculated according to the following equation: Loss TC
(%) = (1 − (Sample/(FaSSIF − Blank)) × 100, where Sample is the con-
centration of the donor samples after incubation, FaSSIF is the
concentration of sodium taurocholate in the pure FaSSIF, and Blank
is the concentration of sodium taurocholate in the blank sample.
2.7. Permeation experiments
Before the permeation experiments, the phospholipid vesicle-
based barriers were incubated with FaB for 1 h. The buffer in the
donor compartment was then removed and replaced by sample
solution. The receiver compartment contained PBS during the incu-
bation and throughout the course of the permeation experiment.
Over a period of 4 h, the inserts were moved to fresh wells contain-
ing PBS at pH 7.4 at certain time intervals to ensure sink conditions.
The amount of drug in the receptor phase was then quantiﬁed
(for details see Section 2.9). The cumulative amount of drug that
had permeated through the barrier was plotted against the time
giving the cumulative ﬂux. When the ﬂux reached steady state,
meaning the slope was  linear, the apparent permeability coefﬁ-
cient (Papp) was calculated according to the following equation:
Papp = dm/dt × (1/A × C0), where dm is the cumulative amount of
drug permeated by the time dt,  A is the area of the insert used and
C0 is the initial donor concentration. Steady state conditions of the
ﬂuxes (r2 ≥ 0.99) were achieved after 1.75 h. For calculation of the
Papp, 4 points of the linear part of the ﬂux curve were used in the
case of cimetidine, nadolol, and griseofulvin and 5 for ketoprofen.
In the case of griseofulvin, additional permeation experiments
were also performed in the presence of BSA (4%) in the receiver
phase.
For all model compounds the mass balance i.e., the quantita-
tive recovery upon completion of the experiment was  calculated by
dividing the amount found after the permeation experiment in the
donor as well as receiver chamber by the initial input of compound
in the donor compartment. The recovery rate was  then expressed
as percentage.
2.8. Electrical resistance measurements
The electrical resistance was measured after each permeation
experiment using a Millicell-ERS (Millipore). The blank resistance
(i.e., resistance of the pure ﬁlter hydrated in PBS) was subtracted
from the total resistance to obtain the actual resistance of the bar-
riers. Finally, these resistance values multiplied by the area of an
insert (0.6 cm2) gave the ﬁnal electrical resistance (ER) in  cm2.
Upon completion of the drug permeability experiments, it was
not necessary to exclude any of the inserts for permeability evalu-
ation since all exhibited satisfactory ER-values.
Table 2
HPLC parameters for the model compounds and sodium taurocholate.
Compound Chromatographic conditions Flow (ml/min)  (nm)
Cimetidine Isocratic 80/20
Watera/methanol
1.0 229
Nadolol 0–6 min  gradient 95/5 to
75/25
Water/acetonitrile,a
thereafter isocratic
1.0 260
Ketoprofen Isocratic 20/80
Water/methanolb
0.8 262
Griseofulvin Isocratic 55/45
Water/acetonitrileb
1.0 291
Taurocholate Isocratic 25/75
Water/methanolb
0.7 200
a Mobile phase contained 0.05% triethylamine, adjusted to pH 3 with phosphoric
acid.
b Mobile phases contained 0.1% formic acid.
2.9. Analysis
Calcein was analysed by ﬂuorescence spectroscopy using a
Fluostar Omega, BMG  Labtech GmbH, Offenburg, Germany (exci-
tation 485 nm,  emission 520 nm). The model compounds as well
as taurocholate were analysed using a Waters 2695 HPLC with
UV detection (Waters 2487 Dual  Absorbance Detector). Sep-
aration was  performed by an Acclaim 120 (C18, 5 m particle
size, 120 A˚, 4.6 mm × 250 mm)  column. Run times, mobile phases
(isocratic in the case of ketoprofen, cimetidine, griseofulvin and
taurocholate, and with gradient in the case of nadolol), ﬂow and
wavelengths are listed in Table 2. The lowest standard concentra-
tions used for each substance were 1.2 M (ketoprofen), 2.0 M
(nadolol), 0.8 M (cimetidine), 0.05 M (griseofulvin) and 5 M
(taurocholate), which in all cases were far above the quantiﬁcation
limits. All samples ranged well within the constraints of the low-
est and highest standard, respectively. The standard curves yielded
linear ﬁts (r2 ≥ 0.999). The software used was Chromeleon 6.80
(Dionex, Hvidovre, Denmark).
The BSA containing samples were cleaned from BSA by adding
two volumes of acetonitrile to one volume of sample as described
by Hubatsch et al. (2007).  As suggested, the samples were then
vortexed and centrifuged (10 min, 15,000 × g). The supernatant was
immediately withdrawn and analysed as per the pure PBS samples.
2.10. Statistical analysis
For statistical analysis, Origin 6.0 (OriginLab Corporation,
Northampton, MA,  USA) was employed. A one-way analysis of vari-
ance (ANOVA) was  performed where p < 0.05 was considered as
signiﬁcant.
3. Results and discussion
3.1. Integrity of the phospholipid vesicle-based permeation
barriers in the presence of FaSSIF
3.1.1. Electrical resistance and calcein permeability
In order to evaluate whether or not FaSSIF affected barrier func-
tion of the PVPA model, two independent assessments of integrity
were performed; measurement of electrical resistance (ER) and
permeability of calcein, a hydrophilic model compound which
exhibits relatively low permeability across lipid bilayers. In tandem,
this approach has previously been shown to conﬁrm the compat-
ibility of the model in the presence of different co-solvents and
surfactants (Fischer et al., 2011; Flaten et al., 2008; Kanzer et al.,
2010). While a decrease in ER may  depend on a variety of factors,
including compromised barrier integrity, any sudden increase in
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Fig. 1. Integrity of the PVPA model in the presence of FaB and FaSSIF in comparison
with Triton X-100 0.5% (positive control): calcein permeability (bars) and ER ().
Values are given as mean ± SD, n = 12. Signiﬁcant differences are denoted by *p < 0.05.
calcein permeability is assumed to exclusively reﬂect leakage of
the barrier. In addition, the presence of barrier phospholipids in
the donor phase, as a sign of partial dissolution of the barrier, has
been shown to correlate with both diminished ER and increased
calcein permeability (Fischer et al., 2011; Flaten et al., 2008).
ER and calcein permeability were measured in the presence of
FaB and FaSSIF following incubation for 4 h (Fig. 1). In the case
of FaSSIF, values for ER and permeability were slightly lower and
higher, respectively, when compared to FaB, but the differences
were not signiﬁcant. Noteworthy, ER- and calcein permeability-
values are somewhat different from earlier published data for the
PVPA model (Flaten et al., 2006b, 2008). Most likely this can be
ascribed to the fact that the ﬁlter area as well as the donor vol-
ume  here are bigger than in the previously employed set-up. We
have chosen larger inserts because the increased ﬁlter area results
in higher ﬂux per time and thus facilitates improved detection of
drug(s), especially those which are poorly soluble. Overall, in our
experimental set-up, it could be concluded that in terms of cal-
cein permeability and ER, the tightness of the PVPA barriers in the
presence of FaSSIF appeared to be maintained.
3.1.2. Barrier structure
To further conﬁrm compatibility of the PVPA model with FaSSIF,
we visualised the ﬂuorescently labelled liposome barrier by CLSM,
both prior to and after exposure to FaSSIF. Although not capable
of identifying nano- and micro-size domains of lipid structure, it
facilitated visualisation of potential defects or holes in the barrier.
Rhodamine ethanolamine is widely used in studies of membrane
fusion, ion permeation and lipid transfer between vesicles. Impor-
tantly, it is not dependent on pH changes or molecular aggregation
Fig. 3. Release of phosphatidylcholine from the PVPA barrier following incubation
with FaB and FaSSIF in comparison to TritonX-100 0.5% (postive control). Values are
given as mean ± SD, n = 9. Signiﬁcant differences are denoted by *p < 0.05.
in the concentration used in this study (Massari et al., 1988). The
results are depicted in Fig. 2. Z-stack images show that the barrier
is composed of lipid-ﬁlled ﬁlter-pore structures with an additional
layer of liposomes atop the ﬁlter. Crucially, in neither barriers incu-
bated with buffer, nor those incubated with FaSSIF, were any larger
aqueous channels penetrating through the ﬁlter observed. This fur-
ther supports our assertion that FaSSIF elicits no obvious defects
in phospholipid structure of the barrier or that it induces partial
solubilisation of the barrier.
3.1.3. Release of phospholipid from the barriers
The aforementioned integrity studies, whereby calcein perme-
ability and ER measurements were employed, showed compatibil-
ity with the model, although the variance was somewhat high. To
further assess barrier integrity we quantiﬁed the release of phos-
pholipid from the barriers using an enzymatic assay. An enhanced
release of phospholipid from the barriers would be indicative of
(partial) barrier disintegration. After 4 h of incubation with FaB,
FaSSIF, and Triton X-100 0.5% (positive control), the amount of
phospholipid measured in the donor phase was similar for both
FaB and FaSSIF, while the positive control showed hugely elevated
levels of PC in the donor (Fig. 3). Thus, in the presence of FaSSIF, the
barriers released approximately the same amount of phospholipid
as that observed following incubation with FaB. This ﬁnding com-
plements our other observations regarding barrier integrity in the
presence of FaSSIF, and veriﬁes that the PVPA barriers remain intact
and are not dissolved in contact with FaSSIF. It is worth mentioning
that despite its aggressive surfactant nature, sodium taurocholate
in the given combination with phosphatidylcholine (i.e., FaSSIF),
appears to be suitably applicable in the PVPA model. This is in con-
trast to a number of other surfactants previously tested (Fischer
et al., 2011).
Fig. 2. CLSM Z-stack images of the PVPA barrier following incubation with phosphate buffer (PBS) (a) and FaSSIF (b). Scale bars are 20 m.
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Fig. 4. Loss of sodium taurocholate in the donor phase versus time during incubation
with FaSSIF. Values are given as mean ± SD, n = 9.
3.1.4. Loss of sodium taurocholate from FaSSIF
The composition of FaSSIF as used here, is derived from Galia
et al. (1998),  which speciﬁes the content of sodium taurocholate
(TC) and phosphatidylcholine (PC) in FaSSIF to be 3 mM and
0.75 mM,  respectively. FaSSIF has been described to contain mixed
TC/PC micelles (Galia et al., 1998; Schwebel et al., 2011). The inﬂu-
ence of bile salts on phospholipid bilayers or liposomes has earlier
been investigated (Nichols, 1986; Schubert et al., 1983). Bile salts, at
increasing mixing ratios, initially form pores within bilayers, then
sequester smaller vesicles and ﬁnally convert bilayers into mixed
micelles (Schubert et al., 1986; Schubert and Schmidt, 1988). Hence,
it could be expected that the sodium taurocholate may  interact in
some way with the phospholipid bilayer structure of the PVPA bar-
riers during permeation studies. Therefore, we  have investigated
the content of sodium taurocholate in the donor phase, while incu-
bated with the barriers. Over a period of 4 h, the amount of sodium
taurocholate in the donor compartment appeared to decrease, lev-
elling off at a loss of ∼30% after 4 h (following subtraction of the
blank). The blank measurement conﬁrmed that only negligible
amounts of taurocholate in the FaSSIF (∼2–4%) adsorbed to plas-
tic surfaces. Thus, the loss of ∼30% after 4 h indicates that TC is
to a large extent bound to or incorporated within the PVPA barri-
ers (Fig. 4). Evidently, there occurs a net transfer of taurocholate
from the donor to the barrier, while the PC concentration in the
donor stays constant. Despite this selective accumulation of tauro-
cholate in the PVPA-barrier, there were only minor changes seen in
barrier tightness, in terms of ER-decrease and calcein permeability-
increase. From the experimental data, it cannot be completely ruled
out whether the observed minimal increase in calcein permeabil-
ity is connected with a formation of aqueous pores spanning the
barrier. This is unlikely, however, since leakage or solubilisation of
unilamellar vesicles has been described to occur ﬁrst from a TC/lipid
ratio of 0.15 or 0.3, respectively, onwards (Schubert et al., 1986). In
the present study, a TC/lipid ratio of 0.05 is estimated under the
assumption that accumulated TC is evenly distributed within the
barrier and the barrier contains 10 mg  PC/cm2 (Flaten et al., 2006a).
This correlates with earlier studies indicating that permeability of
small hydrophilic molecules is ﬁrst increased when TC-binding to
PC-bilayers approaches solubilising concentrations (Albalak et al.,
1996).
3.2. Permeation of model drugs in the presence of FaSSIF
The PVPA-permeability of four model compounds was deter-
mined using FaSSIF in the donor compartment as compared to FaB.
The results are summarised in Figs. 5 and 6. For cimetidine and
Fig. 5. Apparent permeability (Papp) of model drug compounds in FaB, and FaSSIF.
Values are given as mean ± SD, n = 12 (cimetidine and nadolol), n = 16 (ketoprofen).
Signiﬁcant differences are denoted by *p < 0.05.
Fig. 6. Apparent steady state ﬂuxes of griseofulvin in FaB and FaSSIF as well as FaSSIF
in  the donor and BSA (4%, w/v) in the receiver phase. Values are given as mean ± SD,
n  = 12. Signiﬁcant differences are denoted by *p < 0.05.
nadolol, the apparent permeability was  found to be augmented in
FaSSIF as compared to buffer. A somewhat increased permeabil-
ity was also observed in the case of ketoprofen, albeit not reaching
signiﬁcance. For the fourth model compound, griseofulvin, we  have
chosen to present ﬂux data instead of Papp-values (Fig. 6). This is due
to the poor recovery of the compound (see mass balance discussion
in Section 3.3). The ﬂux of griseofulvin was found unchanged in the
presence of FaSSIF when compared to blank buffer solution (i.e.,
FaB). To our knowledge, this study is the ﬁrst report on the inﬂuence
of FaSSIF on permeation models, which exclusively describe passive
permeation. In various Caco-2 permeability studies, the presence of
FaSSIF in the apical compartment either reduced the permeability
of passively transported drugs or showed no effect (Fossati et al.,
2008; Ingels et al., 2002; Lind et al., 2007; Patel et al., 2006). Only a
few reports have found an increase in permeability of model com-
pounds in the presence of FaSSIF (Lakeram et al., 2008). Brouwers
et al. (2006) and Ingels et al. (2004) postulated that the increase of
drug permeability across Caco-2 monolayers may  be a result of Pgp
inhibition induced by taurocholate. Yet, in our case, a Pgp-inﬂuence
can be excluded.
In a recent study with the PVPA model (Fischer et al., 2011),
we have demonstrated that the passive permeability of ketopro-
fen and nadolol in the presence of poloxamer 188 is depressed
in a surfactant concentration-dependent manner. We  concluded
that micelle-associated drug remains inaccessible for perme-
ation. More recently, Miller et al. (2011) have postulated a
solubility–permeability interplay in conjunction with micellar
solubilisation. In the literature there are clear indications for
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Table 3
Recovery rates (%) of the model compounds with different media in permeation
studies. Values are given as mean ± SD (n = 12).
Mediuma Cimetidine Ketoprofen Nadolol Griseofulvin
FaB 95 ± 2 85 ± 2 94 ± 3 31 ± 3
FaSSIF 92 ± 2 87 ± 3 91 ± 2 46 ± 2
FaSSIF + BSAreceiver – – – 52 ± 2
a Medium in the donor phase. The receiver phase consisted of PBS pH 7.4 through-
out, except for FaSSIF + BSAreceiver where 4% (w/v) BSA was added to the receiver
phase.
interactions of three of the model drugs used here with either
TC-micelles or TC/PC-micelles. Nadolol has previously shown an
increased solubility in the presence of TC-micelles and to par-
tition into mixed micelles (de Castro et al., 2001). In addition,
Sheng et al. (2009) reported an enhanced dissolution rate for keto-
profen in FaSSIF. The solubility of griseofulvin was doubled in a
15 mM TC solution (Mithani et al., 1996) while a ten to twenty-fold
increase in solubility was described for various SIF-media (Nielsen
et al., 2001) as compared to buffer. Moreover, Kataoka et al. (2003)
found the dissolution rate of griseofulvin in 5 mM TC enhanced.
Nadolol, ketoprofen and griseofulvin were thus expected to be
present in their micellar form to some extent, which according
to our hypothesis, should result in decreased permeability val-
ues in the presence of FaSSIF. The unchanged or slightly increased
permeabilities observed here may  lead to the assumption that
there is greater complexities underlying this interplay. For exam-
ple, the incorporation of TC in PVPA-barriers may  induce a slight
change in barrier characteristics (below the threshold detectable
by calcein and ER) in terms of small pores (Schubert et al., 1986)
and/or altered partitioning of drugs (de Castro et al., 2001). de
Castro et al. (2001) has reported increasing afﬁnity of nadolol
for mixed cholate/lecithin systems with increasing cholate con-
tent. In the case of griseofulvin, where micellar encapsulation of
this highly lipophilic compound can be assumed, there was still
no diminution in permeability observed. Concurrently, the higher
recovery rates of griseofulvin in the presence of FaSSIF in the donor
phase (see Table 3 and Section 3.3) indicate a steadily higher drug
concentration in the donor compartment. Higher concentrations
in the donor did, however, not affect or enhance the ﬂux. Most
probably, this is due to micellar encapsulation, i.e., the micel-
lar encapsulated fraction of the drug is not available for drug
permeation.
3.3. Effect of FaSSIF on recovery
Recovery can be deﬁned as the quantity recovered in both the
donor and receiver chambers upon completion of the experiment,
and expressed as a percentage of that which was added at time zero.
A satisfactory recovery is crucial to ensure appropriate predictive
power of permeability studies. For example, a low recovery may
reﬂect accumulation in the permeation barrier and/or adsorption to
the experimental apparatus surface. In our opinion, any calculation
of Papp will be compromised in such instances. In the case of cime-
tidine, ketoprofen and nadolol, recovery rates were quite high (i.e.,
>85%) and comparable for buffer and FaSSIF (Table 3). In notable
contrast, the recovery rate calculated for griseofulvin – a compound
of strong lipophilic character – was remarkably low in the presence
of FaB (approx. 31%). In the presence of FaSSIF the recovery rate was
enhanced to a level of 46%. Thus, FaSSIF exerts a beneﬁcial effect
in terms of its inﬂuence on drug adsorption onto the experimen-
tal device(s) and accumulation within the barrier. Collectively, this
ensures that undesirable drug-loss from the donor compartment is
minimised. Similar effects have been observed with the Caco-2 cell
model (Fossati et al., 2008; Ingels et al., 2004).
3.4. Inﬂuence of basolaterally applied bovine serum albumin on
the recovery and ﬂux of griseofulvin in the presence of FaSSIF
BSA is frequently employed to avoid low mass balance due to
adsorption to plastic devices (Hubatsch et al., 2007; Krishna et al.,
2001; Yamashita et al., 2000). At the same time, it provides an
improvement in sink conditions in the receiver phase (Hubatsch
et al., 2007; Krishna et al., 2001). In light of this, we utilised BSA in
the receiver compartment, and investigated the mass-balance and
ﬂux of griseofulvin in the presence of FaSSIF. The recovery rate was
increased to ∼52%, which translates to a 10% increase when com-
pared to FaSSIF alone in the donor phase (∼46%) (Table 3). Most
probably, this can be attributed to avoidance of drug adsorption
to the apparatus surface(s) in the receiver chamber. In addition,
the presence of BSA also served to enhance the ﬂux of griseofulvin
(Fig. 5). It is likely that this can be ascribed to an improvement in
sink conditions. Analogous effects in cellular-based models have
previously been described (Fossati et al., 2008; Ingels et al., 2002).
4. Conclusion
The applicability of FaSSIF in drug permeation studies employ-
ing PVPA barriers was  conﬁrmed by different integrity studies. No
signiﬁcant alterations in calcein permeability or electrical resis-
tance were observed. The release of phospholipid from the barriers
was negligible ruling out partial dissolution. Furthermore, visual
examination of the barrier structure by CLSM revealed no signiﬁ-
cant changes. Notably, sodium taurocholate in the FaSSIF interacted
with the phospholipids of the barrier. Drug permeability-values
were found slightly enhanced or unchanged in the presence of FaS-
SIF, which may  be attributed to micellar encapsulation and/or slight
changes in barrier characteristics due to TC-uptake. Especially for
poorly soluble drugs, FaSSIF improved the performance of PVPA-
permeability studies in terms of markedly enhanced recovery,
while permeability values remained comparable to those observed
in buffer. Moreover, utilisation of BSA in the receiver compartment
appears to reduce unspeciﬁc adsorption to plastic surfaces and
more easily affords sink conditions. At the same time, the some-
what higher cost and complexity associated with the use of FaSSIF
in permeability studies must be considered. However, overall, our
results using the PVPA model suggest that for poorly soluble drugs
a combination of FaSSIF in the donor phase and BSA in the receiver
phase permits superior experimental conditions.
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